Vendor Intelligence Report: Peptide Partners
Published 12 Nov 2026. 40-page investigative report on who is behind Peptide Partners: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 109 Finnrick lab tests, Peptide Partners records 79 pass / 29 fail, for a 72% overall pass rate. The read is sharply product-specific rather than brand-wide: Retatrutide is the clear strength and Ipamorelin also tests well, while TB-500 and CJC-1295 are the avoid lines on the current record. The weaker lines lose more ground under stricter grading, so batch and product selection matter more here than the homepage's broad quality language.
This is not an empty-shell storefront. Public records tie Peptide Partners to Pirsek Technologies and a Sarasota operator/controller, the site publishes batch IDs and a 465-row certificate archive, and the company shows signs of analytical buildout. The limits are equally concrete: legal beneficial ownership is not closed in the public record, no named U.S. fill-finish facility or upstream supplier is disclosed, and no final batch-release authority was found in sources reviewed.
The investigation also follows buyer-facing operational signals that do not show up in purity charts. A vendor-described China raw-material and U.S. fill-finish transition sits beside an admitted pH/COA incident that reached customers. A suspended lookalike domain, a discontinued affiliate portal coexisting with active code-based promotions, and payment-friction evidence including a no-chargeback route observation all affect how a buyer should verify before ordering.
Inside the full report:
- Appendix A Finnrick data, methodology-divergence charts and trajectories for all 10 products
- Wyoming filing, Pirsek policy trail, Sarasota address bridge and unresolved UBO analysis
- 465-row certificate archive broken down by lab, category and manufacturer ID
- Supply-chain review of China raw material, unnamed U.S. fill-finish and the pH/COA incident
- Domain-authentication map covering peptide.partners, the suspended lookalike and Certificate Transparency subdomains
- Affiliate-code, review-surface and payment-rail analysis, including Zelle and QuickBooks signals
Risk assessment
- Product-specific batch/fill consistency risk — high: Weak Finnrick lines are TB-500 34.38% (4 pass/9 fail), CJC-1295 35.62% (4/5), Tesamorelin 51.17% (7/6), and BPC-157 56.53% (7/4); Retatrutide, Ipamorelin, GHK-Cu, and Tirzepatide are stronger choices.
- Affiliate-promotion disclosure risk — high: Prior scan found 20 promoter/coupon surfaces, 19 referral-bearing and many without clear disclosure; current portal says discontinued while affiliate pages/codes continue.
- Upstream supplier/facility opacity risk — medium: Vendor describes China raw material and U.S. fill-finish transition, but upstream suppliers, importer, fill-finish facility and facility registrations are not publicly named.
- Brand-authentication / copycat risk — medium: A Peptide Partners lookalike domain was captured live and is now suspended; the vendor lacks a public authorized-reseller list, known-lookalike warning, or signed anti-counterfeit system.
- Payment/dispute-route risk — medium: A Zelle/no-chargeback path was observed by an affiliate reviewer, the policy names no processor and discourages unwarranted chargebacks, and the vendor says QuickBooks held funds for 180 days.
- Entity/beneficial-ownership transparency risk — medium: Pirsek Technologies LLC and Zachary David Hoff/Zak David are strongly linked to operations, but no member/shareholder/UBO record was retrieved for the Peptide Partners/Pirsek chain.